On May 21, 2026 Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, reported new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Date & Time: Monday, June 1, 2026, 10:30 am – 11:15 am PT

Session Type: Poster
Session Title: Oncology Clinical Diagnosis and Therapy Scientific Session

Session Number: MTA06 – Screen 29
Title: Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment.
Presenter: Neal Shore, Carolina Urologic Research Center
Poster Number: #262453

Date & Time: Tuesday, June 2, 2026, 9:50 am – 10:00 am PT
Session Type: Oral Presentation

Session Title: Prognosis and Novel Imaging Techniques
Session Number: SS30

Location: SS Room 2

Title: Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study
Presenter: Sangwon Han, Asan Medical Center, University of Ulsan College of Medicine

(Press release, Lantheus, MAY 21, 2026, View Source [SID1234665933])

On May 21, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional Fc-enhanced anti-CTLA-4 antibody, with balstilimab (BAL), an anti-PD-1 antibody, in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The full dataset will be presented by Dr. Michael Atkins on May 31, 2026 at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BOT+BAL combination arm included 36 heavily pretreated patients with advanced cutaneous melanoma. Most had disease that had resisted prior checkpoint therapy, and many had poor-risk features, including visceral disease and elevated LDH. In this setting, where patients have often exhausted the benefit of currently available checkpoint approaches, the most meaningful signals were the durability of benefit and survival outcomes observed with BOT+BAL.

In the overall BOT+BAL population, median overall survival was 16.6 months, 42% of patients were alive at two years, and median duration of response was not reached. Among responders, 86% remained in response at 12 months. Confirmed objective response rate was 22%, providing evidence of antitumor activity in a population where durable disease control is difficult to achieve.

Survival and durability were particularly notable in the subgroup of patients whose disease was refractory or resistant to both prior anti-PD-(L)1 and anti-CTLA-4 therapy. Published benchmarks show median overall survival of approximately 13 to 14 months among patients refractory or resistant to both anti-PD-(L)1 and anti-CTLA-4 therapyi,ii. In this dual checkpoint-exposed subgroup, median overall survival was not reached and 64% of patients were alive at two years. Median duration of response was also not reached, with all responders remaining in response at 12 months.

"Patients with advanced melanoma whose disease has progressed after PD-1-based therapy, particularly those also exposed to CTLA-4 therapy, remain difficult to treat. For those without a BRAF mutation, who lack an effective targeted option, the choices after checkpoint therapy are especially limited," said Michael B. Atkins, M.D., Deputy Director, Georgetown Lombardi Comprehensive Cancer Center, and lead author of the presentation. "In that setting, the survival and the durability of response seen with BOT plus BAL stand out, because sustained disease control is exactly what these patients rarely achieve."

"Melanoma has been one of the clearest examples of the transformative potential of immunotherapy, but patients whose disease progresses after PD-1 and CTLA-4 therapy continue to face limited options," said Steven O’Day, M.D., Chief Medical Officer of Agenus. "These findings add to the growing body of evidence supporting BOT plus BAL’s potential to drive meaningful and durable immune responses in tumors that have resisted prior checkpoint approaches. Importantly, the melanoma data are consistent with the durable activity previously reported with BOT plus BAL across other difficult-to-treat and historically immunotherapy-resistant solid tumors, including recent HCC data in a heavily prior IO-treated population."

Safety findings were consistent with the known safety profile of CTLA-4 and PD-1 checkpoint inhibition. In the BOT+BAL combination arm, grade 3 or higher treatment-related adverse events occurred in 36% of patients, with no treatment-related deaths reported. No new safety signals were observed.

The melanoma findings add to previously reported BOT+BAL activity across difficult-to-treat and historically immunotherapy-resistant solid tumors, including recently published data in Liver Cancer evaluating BOT+BAL in heavily immunotherapy-pretreated hepatocellular carcinoma.

"These data reinforce our conviction in BOT+BAL as a mechanistically differentiated CTLA-4-based combination designed to extend the benefit of immunotherapy to patients and tumor types not adequately served by current checkpoint approaches," said Garo Armen, Ph.D., Chairman and Chief Executive Officer of Agenus. "Across melanoma, colorectal cancer and other difficult-to-treat solid tumors, we continue to see a consistent pattern: durable responses and encouraging long-term survival in settings where available options remain limited. That is the foundation of our development strategy and the reason we remain focused on advancing BOT+BAL with urgency."

Key Phase 2 BOT+BAL Melanoma Findings

The Phase 2 C-800-23 study (NCT05529316) evaluated BOT+BAL in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, including patients previously treated with anti-CTLA-4 therapy. The intent-to-treat population included 36 patients treated with BOT 75 mg plus BAL 450 mg every three weeks.

Overall BOT+BAL population, N=36:

Median overall survival: 16.6 months
2-year overall survival rate: 42%
Median duration of response: not reached
12-month duration of response rate: 86%
Confirmed objective response rate: 22%
Clinical benefit rate at 24 weeks: 33%
Prior anti-PD-(L)1 plus anti-CTLA-4 refractory/resistant cohort, n=14:

Median overall survival: not reached
2-year overall survival rate: 64%
Median duration of response: not reached
12-month duration of response rate: 100%
Confirmed objective response rate: 29%
Clinical benefit rate at 24 weeks: 36%
Following the poster session on May 31, 2026, the full poster will be available on the Publications page of the Agenus website.

Presentation Details

Abstract Title: Botensilimab (BOT) ± balstilimab (BAL) in patients (pts) with advanced cutaneous melanoma (cMEL) refractory/resistant (R/R) to anti–PD-(L)1 ± CTLA-4: A phase 2 trial
Abstract No.: 9543

Presenter: Michael B. Atkins M.D.; Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center
Session Title: Poster Session – Melanoma/Skin Cancers
Location: Hall A – Posters and Exhibits
Poster Board: 259
Date/Time: May 31, 2026, 9:00 AM–12:00 PM CDT
About the C-800-23 Phase 2 Melanoma Study

C-800-23 (NCT05529316) is an open-label, global Phase 2 trial evaluating botensilimab with or without balstilimab in patients with advanced cutaneous melanoma refractory or resistant to prior anti-PD-(L)1 therapy, with or without prior anti-CTLA-4 therapy.

The primary endpoint is confirmed objective response rate by RECIST 1.1. Secondary endpoints include duration of response, progression-free survival, overall survival, safety and tolerability. Clinical benefit rate, defined as complete response, partial response or stable disease at 24 weeks or later, was evaluated as an exploratory endpoint.

(Press release, Agenus, MAY 21, 2026, View Source [SID1234665949])

On May 21, 2026 SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, reported the presentation of data on iza-bren (izalontamab brengitecan), BL-M14D1, T-Bren (BL-M07D1), and BL-M05D1, four distinct clinical programs from its antibody drug conjugate (ADC) pipeline, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting taking place May 29 – June 2 in Chicago. Iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories outside of China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data we are presenting at ASCO (Free ASCO Whitepaper) 2026 mark an important inflection point for SystImmune, with multiple late-stage readouts alongside continued expansion of our earlier pipeline," said Dr. Jie D’Elia, Ph.D., Chief Executive Officer of SystImmune. "From randomized Phase III trials of iza-bren to emerging proof-of-concept data across our next-generation ADC programs, we are demonstrating both the clinical potential and scalability of our platform. Together, these advances reinforce our ability to rapidly translate innovative science into differentiated therapies for patients with high unmet need worldwide."

Key data to be presented at ASCO (Free ASCO Whitepaper) include:

Highlighting the continued clinical advancement of iza-bren:

Late-breaking data from the first randomized, Phase III study evaluating iza-bren versus physician’s choice of chemotherapy in unresectable locally advanced or metastatic triple-negative breast cancer patients in China
Safety and efficacy data from a randomized, open label, multi-center, Phase III study evaluating iza-bren vs physician’s choice of chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma in China
Demonstrating breadth of ADC platform with updates from novel ADC programs:

Results from the first Phase I study in China of BL-M14D1, a novel DLL3 directed ADC, in patients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors
Safety and efficacy results from a Phase II study in China evaluating trastuzumab brengitecan (T-bren; BL-M07D1) in patients with recurrent or metastatic ovarian cancer
Results from a Phase II study in China of T-Bren monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer
Results from the first Phase I study in China of BL-M05D1, a novel Claudin 18.2 directed ADC, in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors
"We are particularly encouraged to present the Phase III data for iza-bren compared to standard chemotherapy in TNBC, which further supports its potential to deliver meaningful clinical benefit across multiple tumor types," said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. "In parallel, data from T-Bren, BL-M14D1, and BL-M05D1 highlight the breadth of our ADC portfolio, with early signals of activity and combination potential in several difficult-to-treat cancers. Collectively, these results strengthen our confidence in advancing both iza-bren and our broader pipeline into later-stage development."

Details of the presentations at ASCO (Free ASCO Whitepaper) are below:

Izalontamab brengitecan (iza-bren) versus physician’s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): A randomized phase III study
Trial Reference: BL-B01D1-307 (NCT06382142), China
Session Title: Oral Abstract Session – Breast Cancer (Metastatic)
Abstract: LBA1003
Speaker: Jiong Wu (Shanghai, China)
Session Date & Time: Tuesday, June 2nd, 2026, 9:45 AM-12:45 PM CDT

Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study
Trial Reference: BL-B01D1-305 (NCT06304974), China
Session Title: Oral Abstract Session – Gastrointestinal Cancer (Gastroesophageal, Pancreatic, and Hepatobiliary)
Abstract: 4008
Speaker: Zhihao Lu (Beijing, China)
Session Date & Time: Monday, June 1st, 2026, 9:45 AM-12:45 PM CDT

Phase I study of BL-M14D1, a novel DLL3-directed antibody-drug conjugate (ADC), inpatients with locally advanced or metastatic small-cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), and other solid tumors
Trial Reference: BL-M14D1-101 (NCT06505824), China
Session Title: Oral Abstract Session – Developmental Therapeutics (Molecularly Targeted Agents and Tumor Biology)
Abstract: 3001
Speaker: Wei Li (Shanghai, China)
Session Date & Time: Monday, June 1st, 2026, 8:00 AM-11:00 AM CDT

T-Bren (BL-M07D1) in patients with recurrent or metastatic (R/M) ovarian cancer: Results from two phase II studies
Trial Reference: BL-M07D1-202/203 (NCT06031584/NCT06131450), China
Session Title: Oral Abstract Session – Developmental Therapeutics (Molecularly Targeted Agents and Tumor Biology)
Abstract: 3003
Speaker: Gongyi Zhang (Beijing, China)
Session Date & Time: Monday, June 1st, 2026, 8:00 AM-11:00 AM CDT

Phase II study of izalontamab (SI-B001) in combination with paclitaxel or docetaxel in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Trial Reference: SI-B001-206 (NCT05054439), China
Session Title: Rapid Oral Abstract Session (Head and Neck Cancer)
Abstract: 6019
Speaker: Ye Guo (Shanghai, China)
Session Date & Time: Monday, June 1st, 2026, 4:30 PM-6:00 PM CDT

Phase I study of BL-M05D1, a novel Claudin18.2-directed antibody-drug conjugate (ADC), in patients with locally advanced or metastatic Claudin18.2–expressing solid tumors
Trial Reference: BL-M05D1-101 (NCT06349811), China
Session Title: Poster Session – Developmental Therapeutics (Molecularly Targeted Agents and Tumor Biology)
Abstract: 3030
Speaker: Siyuan Cheng (Beijing, China)
Onsite Poster Display Date: Saturday, May 30th, 2026, 1:30 PM-4:30 PM CDT

Phase II study of T-Bren (BL-M07D1) monotherapy or in combination with pertuzumab in patients with treatment-naïve HER2-positive unresectable locally advanced or metastatic (LA/M) breast cancer
Trial Reference: BL-M07D1-205 (NCT06445400), China
Session Title: Poster Session – Breast Cancer (Metastatic)
Abstract: 1049
Speaker: Yaping Yang (Guangzhou, China)
Onsite Poster Display Date: Monday, June 1st, 2026, 1:30 PM-4:30 PM CDT

About iza-bren
SystImmune, in collaboration with BMS outside of China, is developing iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren’s dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren’s therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.

About SystImmune’s ADC Pipeline Programs (BL-M07D1, BL-M14D1, BL-M05D1)
SystImmune is advancing a portfolio of next-generation antibody-drug conjugates (ADCs) built on its proprietary brengitecan platform, which utilizes a potent topoisomerase I inhibitor payload designed for targeted delivery to tumor cells. The clinical progress of izalontamab brengitecan (iza-bren) provides initial validation of this platform’s potential to deliver meaningful anti-tumor activity across multiple cancer types.

T-Bren (BL-M07D1), BL-M14D1, and BL-M05D1 each incorporate the brengitecan payload and linker technology, paired with distinct targeting antibodies to address different tumor-associated antigens.

T-Bren (BL-M07D1) targets HER2, a well-established driver across multiple solid tumors, enabling targeted delivery of the brengitecan payload to HER2-expressing cancer cells.
BL-M14D1 targets DLL3, which is highly expressed in small-cell lung cancer and neuroendocrine tumors, facilitating selective delivery of the brengitecan payload to DLL3-positive tumor cells.
BL-M05D1 targets Claudin 18.2, a protein highly expressed in tumors such as pancreatic and gastric cancers, enabling targeted cytotoxic activity in Claudin 18.2–expressing tumors.
Across these programs, SystImmune’s brengitecan platform is designed to combine tumor-specific targeting with efficient payload delivery, with the goal of improving therapeutic index and expanding treatment options for patients with difficult-to-treat cancers.

(Press release, SystImmune, MAY 21, 2026, View Source [SID1234665965])

On May 21, 2026 Pliant Therapeutics, Inc. (Nasdaq: PLRX) reported a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors

Presenter: Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center
Session: Developmental Therapeutics – Immunotherapy
Date: Saturday, May 30, 2026, 1:30 – 4:30 p.m. Central Time
Location: Hall A, Poster 467b

FORTIFY – PLN-101095 Phase 1b Indication Expansion Trial

PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.

(Press release, Pliant Therapeutics, MAY 21, 2026, View Source [SID1234665981])

On May 21, 2026 Novartis reported it will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT," said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. "With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients."

Key ASCO (Free ASCO Whitepaper) data highlights include:

Abstract Title Abstract Number/
Presentation Details
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [177Lu]Lu-PSMA-617

225Ac-PSMA-617
AcTION: Phase 1 Study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [177Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020
Rapid Oral
May 31, 4:30pm – 6:00pm CDT

Abstract # 5010
Oral
June 1, 3:00pm – 4:30pm CDT

Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP)

Abstract #6583
Poster
June 1, 9:00am – 12:00pm CDT
Kisqali (ribociclib)

Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC)

Abstract #501
Oral
May 30, 1:15pm – 4:15pm CDT
Real-World (RW) Post-Progression Outcomes Following First-Line (1L) Ribociclib (RIB) + Aromatase Inhibitor (AI) Versus AI Alone in African American and Low Socio-Economic Status (SES) Patients (Pts) With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) in the US

Abstract #1073
Poster
June 1, 1:30pm – 4:30pm CDT

Real-World (RW) Post-Progression Outcomes After First-Line (1L) Treatment With Ribociclib + an Aromatase Inhibitor (AI) vs AI Alone in US Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) Abstract # e13044
Online publication

Key EHA (Free EHA Whitepaper) data highlights include: 

Abstract Title Abstract Number/ Presentation Details
Scemblix (asciminib)

ASC4FIRST wk 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Abstract # S160
Oral
June 11, 4:45pm – 6:00pm CEST
Ianalumab (VAY736)
Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results From the VAYHIT2 Phase 3 Trial

Abstract # PF1340
Poster
June 12, 6:45pm – 7:45pm CEST
Pelabresib (DAK539)
Pelabresib Monotherapy in Myelofibrosis After Janus Kinase Inhibitor Failure: Results From Arm 1 of the Open-Label, Phase 2 MANIFEST Study

Abstract # PS1987
Poster
June 13, 6:45pm – 7:45pm CEST
Rapcabtagene autoleucel (YTB323)
Safety, Cellular Kinetics and Early Efficacy of Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured Autologous CD19 CAR-T Therapy, in Severe, Refractory Autoimmune Diseases

Abstract # PF1241
Poster
June 12, 6:45pm – 7:45pm CEST
Fabhalta (iptacopan)
Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from APPLY, APPOINT and roll-over extension program

Abstract #PS1788
Poster
June 13, 6:45pm – 7:45pm
CEST

Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program Abstract # PS1797
Poster
June 13, 6:45pm – 7:45pm
CEST

(Press release, Novartis, MAY 21, 2026, View Source [SID1234665899])